Based on the Carl Zeiss Meditec AG stock forecast from 0 analysts, the average analyst target price for Carl Zeiss Meditec AG is not available over the next 12 months. Carl Zeiss Meditec AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Carl Zeiss Meditec AG is Neutral, which is based on 5 positive signals and 5 negative signals. At the last closing, Carl Zeiss Meditec AG’s stock price was EUR 45.80. Carl Zeiss Meditec AG’s stock price has changed by -7.10% over the past week, -19.51% over the past month and -54.43% over the last year.
No recent analyst target price found for Carl Zeiss Meditec AG
No recent average analyst rating found for Carl Zeiss Meditec AG
Company Overview Carl Zeiss Meditec AG
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG. Address: Goschwitzer Strasse 51-52, Jena, Germany, 07745 Read Less
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye ...Read More
Frequently Asked Questions About Carl Zeiss Meditec AG (AFX:XETRA) Stock
Stock Target Advisor's fundamental analysis for Carl Zeiss Meditec AG's stock is Neutral.
AFX:XETRA stock's dividend yield is 1.95%.
Our analysis grades AFX:XETRA stock's dividend yield at C-. This means that AFX:XETRA stock's dividend yield is above 71% of the stocks in the Medical Instruments & Supplies sector in the XETRA exchange.
Based on this AFX:XETRA may be a average dividend stock for its sector.
Unfortunately we do not have enough data on AFX:XETRA's stock to indicate what its average analyst target is.
AFX:XETRA stock's Price/Earning ratio is 24.98.
Our analysis grades AFX:XETRA stock's Price / Earning ratio at C-. This means that AFX:XETRA stock's Price/Earning ratio is above 29% of the stocks in the Medical Instruments & Supplies sector in the XETRA exchange.
Based on this AFX:XETRA may be undervalued for its sector.
The last closing price of AFX:XETRA's stock was EUR 45.80.
The most recent market capitalization for AFX:XETRA is EUR 5.17B.
Unfortunately we do not have enough analyst data on AFX:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Carl Zeiss Meditec AG's stock.
As per our most recent records Carl Zeiss Meditec AG has 4,823 Employees.
Carl Zeiss Meditec AG's registered address is Goschwitzer Strasse 51-52, Jena, Germany, 07745.
You can get more information about it from Carl Zeiss Meditec AG's website at https://www.zeiss.de/meditec-ag/home.html.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Carl Zeiss Meditec AG (AFX:XETRA) Stock
Stock Target Advisor's fundamental analysis for Carl Zeiss Meditec AG's stock is Neutral.
AFX:XETRA stock's dividend yield is 1.95%.
Our analysis grades AFX:XETRA stock's dividend yield at C-. This means that AFX:XETRA stock's dividend yield is above 71% of the stocks in the Medical Instruments & Supplies sector in the XETRA exchange.
Based on this AFX:XETRA may be a average dividend stock for its sector.
Unfortunately we do not have enough data on AFX:XETRA's stock to indicate what its average analyst target is.
AFX:XETRA stock's Price/Earning ratio is 24.98.
Our analysis grades AFX:XETRA stock's Price / Earning ratio at C-. This means that AFX:XETRA stock's Price/Earning ratio is above 29% of the stocks in the Medical Instruments & Supplies sector in the XETRA exchange.
Based on this AFX:XETRA may be undervalued for its sector.
The last closing price of AFX:XETRA's stock was EUR 45.80.
The most recent market capitalization for AFX:XETRA is EUR 5.17B.
Unfortunately we do not have enough analyst data on AFX:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Carl Zeiss Meditec AG's stock.
As per our most recent records Carl Zeiss Meditec AG has 4,823 Employees.
Carl Zeiss Meditec AG's registered address is Goschwitzer Strasse 51-52, Jena, Germany, 07745.
You can get more information about it from Carl Zeiss Meditec AG's website at https://www.zeiss.de/meditec-ag/home.html.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AFX:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
